ClinicalTrials.gg

Pulmonary Embolism clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 832 studies for Pulmonary Embolism across more than 10 countries. 171 are recruiting or about to start. 455 of them are mainly about Pulmonary Embolism (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,007 studies for Pulmonary Embolism. How that becomes 832 here

This page counts the studies the registry files under Pulmonary Embolism, and those it files under no condition that list Pulmonary Embolismthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,007Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −9List Pulmonary Embolism as a condition, but the registry did not file them under itMost often written as “Pulmonary Embolism Acute” (5), “Acute Pulmonary Embolism” (2), and “Pulmonary Embolism Subacute Massive” (2). The registry filed them under other conditions only, most often Embolism (2) and Myocardial Infarction (2).
  3. −167Match it another way29 name it in the title, 4 in a keyword, and 134 by a synonym or other text the search reads.
  4. 831Counted here and found by its search48 of them list Pulmonary Embolism in their own words; the registry filed them under no condition.
  5. +1
    Counted here, but its search does not find them
  6. 832The count on this page

Status

Completed
445
Recruiting
129
Status unknown
107
Terminated
48
Not yet recruiting
39
Withdrawn
30

Phase

Phase 3
84
Phase 4
70
Phase 2
39
Phase 1
15
Early Phase 1
12

Where

United States
236
France
138
Canada
74
China
72
Spain
60
Italy
57

Who develops what

Add Pulmonary Embolism to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 3 companies, 0 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Regeneron Pharmaceuticals and Suzhou Ribo Life Science here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
apixabanRecent, repeated
Evidence
  • NCT07493304 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Apixaban” · registered Mar 2026
  • NCT05171049 · Anthos Therapeutics, Inc. · Phase 3 · comparator · “Apixaban” · registered Nov 2021
Bristol-Myers Squibb59% of its industry studiesUS: off-patent, 1 generic marketedEU: off-patent, 1 generic authorized22 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 17 May 2027 est.cenvacibart · Regeneron Pharmaceuticals · Phase 3 registry mapping onlyvs AspirinNCT07213778 REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants — primary endpoint: Incidence of the composite endpoint of symptomatic VTE and all-cause death · 2,000 enrolled
  • Jul 2027 est.vortosiran · Suzhou Ribo Life Science Co., Ltd. · Phase 2 named, not the main aimNCT07850453 Vortosiran for VTE Prevention — primary endpoint: Primary objective · 150 enrolled
  • 31 Oct 2027 est.isoquercitrin · Quercis Pharma AG · Phase 3 registry mapping onlyNCT06861088 The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer — primary endpoint: Effectiveness of Kinisoquin™ · 480 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pulmonary Embolism studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Factor Xa inhibitors 8 open · Thrombolytics 1 open · NSAIDs 1 open

Coming up

62studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger. 9 (7%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 9 (7%) take healthy volunteers.

Recruiting studies that take each age, of 129
AgeWomenMen
105 (4%)5 (4%)
18127 (98%)126 (98%)
30129 (100%)128 (99%)
40129 (100%)128 (99%)
50129 (100%)128 (99%)
65128 (99%)127 (98%)
75126 (98%)125 (97%)
85121 (94%)120 (93%)

Across all 832 studies, recruiting or not: 8% stop at 75 or younger and 3% at 65; 10% take children; 3% are for women only and <1% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pulmonary Embolism studies take

Of 31 phase 3 interventional studies under Pulmonary Embolism, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 336 mo28–57 · 31 studies——
Phase 447 mo32–82 · 24 studies——
Interventional, no phase25 mo15–51 · 150 studies—27 mo15–55 · 125 studies
Observational47 mo21–105 · 160 studies—49 mo21–119 · 135 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 832. Browse all 832 → or search them.